Aptamers Market to Surge Past US$ 10,407 Million by 2025 due to Widened Application Area

The Global Aptamers Market was valued at US$ 2,304.7 million in 2016 and is projected to expand at a CAGR of 18.4% during the forecast period (2017–2025), as highlighted in a new report published by Coherent Market Insights. Technological advancements, increasing healthcare expenditure by governments, rising prevalence of lifestyle related diseases projected to have a meteoric growth of the aptamers market over the forecast period.

Request for sample copy of this report : https://www.coherentmarketinsights.com/insight/request-sample/774

Numerous advantage of aptamers over antibodies provides a lucrative growth of the global aptamers market. Aptamers have been identified for potential therapeutic and diagnostic purposes, which gain the interest of the scientists within basic and clinical sciences to detect, analyze and quantify these small molecules for further discoveries and is expected to fuel the growth of aptamers market. Aptamer products can also be used as biosensors to act on proteins for biomedical diagnostic applications. This is expected to be a key growth segment in the market in the near future. Furthermore, clinical trials undertaken in aptamer development by various companies would be extremely useful to pharmaceutical industry to discover and develop new drugs.

Many manufacturers are focusing on obtaining aptamers with sufficiently high binding affinities for various kinds of diseases. In September 2015, NeoNeuro has been granted support from BPIfrance Financement under the PIA-1 program for the use of aptamers as a diagnostic and therapeutic tools in Alzheimer’s disease.

Various healthcare companies are actively investing in furthering clinical trials of aptamers in novel applications, which in turn would significantly enhance market growth.

Markets such as Japan, China, Brazil, and India are largely untapped are expected to grow over the forecast period, owing to growing demand for cost effective therapeutics and initiatives taken by key players to expand and increase product distribution to capitalize on highly lucrative growth opportunities in these countries. A technology shift has been observed in the global healthcare sector, with manufacturers focusing on highly advanced techniques for the isolation of high affinity and high selectivity aptamers. For instance, the collaboration of Siva Therapeutics with SomaLogic, Inc., in March 2014, to assess the ability of Somalogic’s SOMAmers to target gold nanorods in cell-based assays will promise to shed light on basic science as well as new product potential about the dynamics of targeting nanorods with aptamers.

Get discount on this report : https://www.coherentmarketinsights.com/insight/request-discount/774

Key takeaways of the Aptamers Market:

The global aptamers market is expected to expand at a CAGR of 18.4% during the forecast period (2017–2025) as there exists major market potential, especially in Asia Pacific, Latin America, Middle East, and Africa.

Nucleic acid aptamers is mainly used as a substitute for protein-based targeting approaches, owing to better chemical stability and thermodynamic compared to peptide therapeutics

Diagnostics is the major application of aptamers, as it is widely used for molecular imaging, biomarker discovery, drug discovery, and other diagnostic purposes

Some of the major players involved in global aptamers market are Ophthotech Corporation, Aptamer Sciences, Inc., Novartis AG, SomaLogic, Inc., NeoNeuro SAS, Aptagen.

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1–206–701–6702
E-mail:sales@coherentmarketinsights.com
Website:https://www.coherentmarketinsights.com

This release was published on openPR.